| Ident. | Authors (with country if any) | Title |
|---|
| 000005 |
Michel Panisset [Canada] ; Jack J. Chen [États-Unis] ; Sean H. Rhyee [États-Unis] ; Jill Conner [États-Unis] ; Julie Mathena [États-Unis] | Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO) |
| 000006 |
Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
| 000010 |
YOUN JU LEE [Corée du Sud] ; So-Young Choi [Corée du Sud] ; Jae H. Yang [Corée du Sud] | NMDA receptor-mediated ERK 1/2 pathway is involved in PFHxS-induced apoptosis of PC12 cells |
| 000044 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 000101 |
Dominic Nadeau [Canada] ; Isabelle Giroux [Canada] ; Julie Dufour [Canada] ; Martine Simard [Canada] | Jeu pathologique chez les patients atteints de la maladie de Parkinson |
| 000153 |
Marija Usenovic [États-Unis, Croatie] ; Adam L. Knight [États-Unis] ; Arpita Ray [États-Unis] ; Victoria Wong [Canada] ; Kevin R. Brown [Canada] ; Guy A. Caldwell [États-Unis] ; Kim A. Caldwell [États-Unis] ; Igor Stagljar [Canada] ; Dimitri Krainc [États-Unis] | Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity |
| 000183 |
Pierre J. Blanchet [Canada] ; Louise Normandeau [Canada] ; Pierre H. Rompre [Canada] | Comparing three screening tools for drug-induced parkinsonism in patients with advanced schizophrenia: A pilot study |
| 000375 |
C. Gibrat [Canada] ; M. Bousquet [Canada] ; M. Saint-Pierre [Canada] ; D. Levesque [Canada] ; F. Calon [Canada] ; C. Rouillard [Canada] ; F. Cicchetti [Canada] | Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor |
| 000410 |
Heather S. Boudreau [Canada] ; Karmen M. Krol [Canada] ; Joseph K. Eibl [Canada] ; Linda D. Williams [Canada] ; John P. Rossiter [Canada] ; Vincent P. Palace ; Gregory M. Ross [Canada] | The association of metal ion exposure with α-synuclein-like immunoreactivity in the central nervous system of fish, Catostomus commersoni |
| 000594 |
Mélanie Bourque [Canada] ; BIN LIU [États-Unis] ; Dean E. Dluzen [États-Unis] ; Therese Di Paolo [Canada] | Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity |
| 000604 |
A. Jon Stoessl [Canada] ; Michael G. Kaplitt [États-Unis] ; Andrew Feigin [États-Unis] ; Chengke Tang [États-Unis] ; Helen L. Fitzsimons ; Paul Mattis [États-Unis] ; Patricia A. Lawlor [Nouvelle-Zélande] ; Ross J. Bland ; Deborah Young [Nouvelle-Zélande] ; Kristin Strybing [États-Unis] ; David Eidelberg [États-Unis] ; Matthew J. During [États-Unis, Nouvelle-Zélande] | Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease : an open label, phase I trial. Commentary |
| 000613 |
YU YAO [Canada] ; Amandio Vieira [Canada] | Protective activities of Vacciniutn antioxidants with potential relevance to mitochondrial dysfunction and neurotoxicity |
| 000630 |
K. V. Rama Rao [États-Unis] ; P. V. B. Reddy [États-Unis] ; A. S. Hazell [Canada] ; M. D. Norenberg [États-Unis] | Manganese induces cell swelling in cultured astrocytes |
| 000676 |
Murray M. Finkelstein [Canada] ; Michael Jerrett [États-Unis] | A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities |
| 000690 |
Martine Saint-Pierre [Canada] ; Marie-Eve Tremblay [Canada] ; Attila Sik [Canada] ; Robert E. Gross [États-Unis] ; Francesca Cicchetti [Canada] | Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats |
| 000758 |
J. Lewis [États-Unis] ; G. Bench [États-Unis] ; O. Myers [États-Unis] ; B. Tinner [Canada] ; W. Staines [Canada] ; E. Barr [États-Unis] ; K. K. Divine [États-Unis] ; W. Barrington [États-Unis] ; J. Karlsson [États-Unis] | Trigeminal uptake and clearance of inhaled manganese chloride in rats and mice |
| 000785 |
Guy Chouinard [Canada] ; Howard C. Margolese [Canada] | Manual for the Extrapyramidal Symptom Rating Scale (ESRS) |
| 000809 |
Véronique Sgambato-Faure [France] ; Virginie Buggia [France] ; Frangois Gilbert [Canada] ; Daniel Levesque [Canada] ; Alim-Louis Benabid [France] ; Francois Berger [France] | Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-lnduced behavioral sensitization in dyskinetic rats |
| 000826 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
| 000860 |
S. Mccarthy [Canada] ; M. Somayajulu [Canada] ; M. Sikorska [Canada] ; H. Borowy-Borowski [Canada] ; S. Pandey [Canada] | Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10 |
| 000866 |
Louise Normandin [Canada] ; Linda Ann Beaupre [Canada] ; Fariba Salehi [Canada] ; Annie St.-Pierre [Canada] ; Greg Kennedy [Canada] ; Donna Mergler [Canada] ; Roger F. Butterworth [Canada] ; Suzanne Philippe [Canada] ; Joseph Zayed [Canada] | Manganese distribution in the brain and neurobehavioral changes following inhalation exposure of rats to three chemical forms of manganese |
| 000885 |
Anne Beuter [Canada] ; Roderick Edwards [Canada] | Effect of chronic exposure to methylmercury on eye movements in Cree subjects |
| 000895 |
Kerry B. Goralski [Canada] ; Kenneth W. Renton [Canada] | Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats |
| 000909 |
Roger F. Butterworth [Canada] | Thiamin deficiency and brain disorders |
| 000922 |
J. G. Nutt [États-Unis] ; K. J. Burchiel [États-Unis] ; C. L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; A. E. Lang [Canada] ; E. R. Jr Laws [États-Unis] ; A. M. Lozano [Canada] ; R. D. Penn [États-Unis] ; R. K. Jr Simpson [États-Unis] ; M. Stacy [États-Unis] ; G. F. Wooten [États-Unis] | Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD |
| 000927 |
Simon Lemay [Canada] ; Pierre Blanchet [Canada] ; Sylvain Chouinard [Canada] ; Hélène Masson [Canada] ; Valérie Soland [Canada] ; Marc-André Bedard [Canada] | Poor tolerability of a transdermal nicotine treatment in Parkinson's disease |
| 000941 |
Ajit Kumar [Canada] ; ZHIGAO HUANG [Canada] ; Raul De La Fuente-Fernandez [Canada] | Mechanisms of motor complications in treatment of Parkinson's disease |
| 000943 |
Larissa Takser [France] ; Donna Mergler [Canada] ; Georgette Hellier [France] ; Josiane Sahuquillo [France] ; Guy Huel [France] | Manganese, monoamine metabolite levels at birth, and child psychomotor development |
| 000966 |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
| 000967 |
Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis] | Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis |
| 000970 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 000984 |
Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada] | Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil |
| 000A11 |
I. Khabazian [Canada] ; J. S. Bains [Canada] ; D. E. Williams [Canada] ; J. Cheung [Canada] ; J. M. B. Wilson [Canada] ; B. A. Pasqualotto [Canada] ; S. L. Pelech [Canada] ; R. J. Andersen [Canada] ; Y.-T. Wang [Canada] ; L. Liu [Canada] ; A. Nagai [Canada] ; S. U. Kim [Canada] ; U-K. Craig ; C. A. Shaw [Canada] | Isolation of various forms of sterol β-d-glucoside from the seed of Cycas circinalis: neurotoxicity and implications for ALS-parkinsonism dementia complex |
| 000A13 |
Frédéric Calon [Canada] ; Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias |
| 000A42 |
Louise Normandin [Canada] ; Gaétan Carrier [Canada] ; Phillip F. Gardiner [Canada] ; Greg Kennedy [Canada] ; Alan S. Hazell [Canada] ; Donna Mergler [Canada] ; Roger F. Butterworth [Canada] ; Suzanne Philippe [Canada] ; Joseph Zayed [Canada] | Assessment of bioaccumulation, neuropathology, and neurobehavior following subchronic (90 days) inhalation in Sprague-Dawley rats exposed to manganese phosphate |
| 000A43 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Othman Ghribi [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Pierre J. Blanchet [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Alteration of glutamate receptors in the striatum of dyskinetic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment |
| 000A66 |
Erik Ch. Wolters [Pays-Bas] | Psychiatric complications in the treatment of Parkinson's disease |
| 000A83 |
A. Y. Alemdar [Canada] ; K. A. Baker [Canada] ; D. Sadi [Canada] ; V. C. Mcalister [Canada] ; I. Mendez [Canada] | Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats |
| 000A84 |
Ron Levy [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] ; Peter Pahapill [États-Unis] ; John Romas [Canada] ; Jean Saint-Cyr [Canada] ; William D. Hutchison [Canada] ; Andres M. Lozano [Canada] | Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms |
| 000A89 |
Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada] | Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials |
| 000B13 |
ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
| 000B26 |
Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte | Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD |
| 000B32 |
Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover |
| 000B36 |
Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] | Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis |
| 000B46 |
D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada] | The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease |
| 000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
| 000B58 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 000B89 |
Maria C. Yang [Canada] ; Allan J. Mclean [Canada] ; Laurent P. Rivory [Australie] ; David G. Le Couteur [Canada] | Hepafic disposition of neurotoxins and pesticides |
| 000B94 |
C. S. Lee [Canada] ; M. A. Cenci [Suède] ; M. Schulzer [Canada] ; A. Björklund [Suède] | Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease |
| 000B95 |
J. M. Van Kampen [Canada] ; A. J. Stoessl [Canada] | Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia |
| 000C34 |
A. Beuter [Canada] ; A. De Geoffroy [Canada] ; R. Edwards [Canada] | Quantitative analysis of rapid pointing movements in Cree subjects exposed to mercury and in subjects with neurological deficits |
| 000C39 |
D. B. King [Canada] | Parkinson's disease : Levodopa complications |
| 000C70 |
J. Rivest [Canada] ; C. L. Barclay [Canada] ; O. Suchowersky [Canada] | COMT inhibitors in Parkinson's disease |
| 000C74 |
A. Beuter [Canada] ; A. De Geoffroy [Canada] ; R. Edwards [Canada] | Analysis of rapid alternating movements in Cree subjects exposed to methylmercury and in subjects with neurological deficits |
| 000C78 |
A. Hadjtahar [Canada] ; P. J. Bedard [Canada] | Comprendre et traiter les dyskinésies induites par la levodopa |
| 000C90 |
A. Samii [Canada] ; S. R. Letwin [Canada] ; D. B. Calne [Canada] | Prospects for new drug treatment in idiopathic parkinsonism |
| 000D53 |
I. H. Richard [États-Unis] ; R. Kurlan [États-Unis] ; C. Tanner [États-Unis] ; S. Factor [États-Unis] ; J. Hubble [États-Unis] ; O. Suchowersky [Canada] ; C. Waters [États-Unis] | Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease |
| 000D60 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | R(-)-deprenyl potentiates dopamine induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells |
| 000D61 |
A. F. Miranda [Canada] ; R. J. Boegman [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] | Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid |
| 000D68 |
P. A. Rochon [Canada] ; J. H. Gurwitz [États-Unis] | Optimising drug treatment for elderly people : the prescribing cascade |
| 000D89 |
M. Novak [Hongrie, Canada] ; C. M. Shapiro [Canada] | Drug-induced sleep disturbances : Focus on nonpsychotropic medications |
| 000D91 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells : effects of oxidative stress and antioxidative factors |
| 000E13 |
P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada] | Remoxipride in the treatment of levodopa-induced psychosis |
| 000E43 |
AGDU'L-MISSAGH GHADIRIAN [Canada] ; L. Annable ; M.-C. Belanger ; G. Chouinard | A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients |
| 000E50 |
A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada] | Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis |
| 000E58 |
F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex |
| 000E60 |
P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. Bedard | Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ? |
| 000E72 |
P. J. Bedard [Canada] | D-1 receptor in neurology and psychiatry : an overview : The role of D-1 dopamine receptors in neurology and psychiatry |
| 000E98 |
B. P. Connop [Canada] ; N. G. Rolfe ; R. J. Boegman [Canada] ; K. Jhamandas [Canada] ; R. J. Beninger | Potentiation of NMDA-mediated toxicity on nigrostriatal neurons by a low dose of 7-nitro indazole |
| 000E99 |
F. J. G. Vingerhoets [Canada] ; B. J. Snow [Canada] ; J. W. Tetrud ; J. W. Langston ; M. Schulzer [Canada] ; D. B. Calne [Canada] | Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions |
| 000F01 |
R. J. Uitti [Canada] ; B. J. Snow [Canada] ; H. Shinotoh [Canada] ; F. J. G. Vingerhoets [Canada] ; M. Hayward [Canada] ; S. Hashimoto ; J. Richmond ; S. P. Markey ; C. J. Markey ; D. B. Calne [Canada] | Parkinsonism induced by solvent abuse |
| 000F04 |
D. Mergler [Canada] ; G. Huel [Canada] ; R. Bowler ; A. Iregren [Canada] ; S. Belanger [Canada] ; M. Baldwin ; R. Tardif [Canada] ; A. Smargiassi [Canada] ; L. Martin | Nervous system dysfunction among workers with long-term exposure to manganese |
| 000F05 |
D. B. Calne [Canada] ; N.-S. Chu ; C.-C. Huang ; C.-S. Lu ; W. Olanow | Manganism and idiopathic parkinsonism : similarities and differences |
| 000F14 |
A. Beuter [Canada] ; D. Mergler [Canada] ; A. De Geoffroy [Canada] ; L. Carriere [Canada] ; S. Belanger [Canada] ; L. Varghese [Canada] ; J. Sreekumar [Canada] ; S. Gauthier | Diadochokinesimetry : a study of patients with Parkinson's disease and manganese exposed workers |
| 000F45 |
P. Blanchet [Canada] ; P. J. Bedard [Canada] ; D. R. Britton ; J. W. Kebabian | Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys |
| 000F49 |
R. W. Lam [Canada] | Chronic schizophrenia and idiopathic Parkinson's disease |
| 001024 |
J. C. S. Furtado [Canada] ; M. F. Mazurek | MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease |
| 001031 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
| 001041 |
J. Zayed ; P. Andre ; J. C. Panisset ; S. Ducic ; G. Campanella ; M. Roy ; G. Kennedy ; C. Delisle | Contamination environnementale par les métaux et maladie de Parkinson |
| 001065 |
R. T. Ross | Drug-induced Parkinsonism and other movement disorders |
| 001074 |
E. C. Wolters ; T. A. Hurwitz ; E. Mak ; P. Teal ; F. R. Peppard ; R. Remick ; S. Calne ; D. B. Calne | Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis |
| 001087 |
E. C. Wolters ; C.-C. Huang ; C. Clark ; R. F. Peppard ; J. Okada ; N.-S. Chu ; M. J. Adam ; T. J. Ruth ; D. Li ; D. B. Calne | Positron emission tomography in manganese intoxication |
| 001100 |
E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. Calne | Clozapine: an antipsychotic agent in Parkinson's disease? |
| 001131 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease |
| 001132 |
J. H. Thakar ; M. N. Hassan ; J. D. Grimes | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), its metabolite cyperquat (MPP+) and energy transduction in mitochondria from rat striatum and liver |
| 001149 |
T. L. Perry ; S. Hansen ; K. Jones | Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice |
| 001161 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets |
| 001170 |
T. L. Perry ; VOON WEE YONG ; R. A. Wall ; K. Jones | Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse |
| 001172 |
J. H. Moss ; D. E. Stewart | Iatrogenic Parkinsonism in Huntington's chorea |
| 001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
| 001188 |
R. J. Uitti ; A. H. Rajput ; E. M. Ashenhurst ; B. Rozdilsky | Cyanide-induced parkinsonism: a clinicopathologic report |
